| 摘要: |
| 目的：探讨CD166在胃肠胰神经内分泌肿瘤(gastroenteropancreatic neuroendocrine neoplasm， GEP-NEN)中的表达及临床病理意义与预后价值。 方法：收集嘉兴市第二医院2011年1月——2022年12月GEP-NEN 141例，复习HE切片，按2019年出版的第5版《世界卫生组织（WHO）消化系统肿瘤分类》GEP-NEN 诊断标准进行分类。采用免疫组化方法检测CD166的蛋白表达，分析CD166表达与各临床病理参数以及预后之间的相关性。 结果：CD166表达强阳性率为90.8%(128/141)，CD166在神经内分泌瘤（neuroendocrine tumor，NET）G1、NET G2、NET G3和神经内分泌癌 (neuroendocrine carcinoma，NEC)组间强阳性表达率有显著差异（P=0.006）,尤其G1到G3表达强度有逐渐减少趋势（97.8% vs 73.7% vs 33.0%）； 除此以外，CD166在小细胞NEC和大细胞NEC之间强阳性表达率也有差异（P=0.012）。减少的CD166表达与淋巴结转移有关（P=0.009），但与性别、年龄、肿瘤大小，生存时间没有显著相关性。结论： CD166在GEP-NEN中大部分呈强阳性表达，其表达率降低与不良的临床病理特征（GEP-NEN分级升高，淋巴结转移）有关，与生存时间无关。小细胞NEC比大细胞NEC更可能对CD166表达强阳性，可以辅助鉴别诊断。 |
| 关键词: 神经内分泌肿瘤 CD166 临床病理意义 |
| DOI： |
| 分类号: |
| 基金项目: |
|
| Expression of CD166 in gastroenteropancreatic neuroendocrine neoplasm and its clinicopathlogical significance |
|
Shen Wenyan, Zhou Quan, Xu Jianqiu, Wang Chunhua, Yu Yawei
|
|
the Second Hospital of Jiaxing
|
| Abstract: |
| Objective To investigate the expression、clinicopathlogical significance and prognosis value of CD166 in GEP-NEN (gastroenteropancreatic neuroendocrine neoplasm). Methods A total of 141 GEP-NEN diagnosed from January 2011 to December 2022 at the Second Hospital of Jiaxing were identified and included. The cases were reviewed and classified based on 5th WHO classification of Digestive tumors. The expression of CD166 was detected by immunohistochemistry, and the correlation between the expression of CD166 and clinical pathological parameters and prognosis was analyzed. Results Strong CD166 expression was observed in 90.8 % (128/141) of all specimens, the expression was significantly different between NET(neuroendocrine tumor) G1 group、NET G2 group、NET G3 group and NEC (neuroendocrine carcinoma) Group (P=0.006). In particular, the expression of G1 to G3 decreased gradually (97.8% vs 73.7% vs 33.0%). Additionly, CD166 expression was significantly different between small cell neuroendocrine carcinoma and large cell neuroendocrine carcinoma（P =0.012）. Reduction of CD166 expression was associated with lymph node metastasis（P=0.009）. However, the strong expression rate of CD166 was not significantly correlated with gender, age, tumor size and survival time. Conclusions Most of CD166 was strongly positive in GEP-NEN and reduction of expression was associated with adverse tumor characteristics(the grade of GEP-NEN and lymph node metastasis). Small cell neuroendocrine carcinoma was more likely to be strongly positive for CD166 than large cell neuroendocrine carcinoma, which can assist in differential diagnosis. |
| Key words: neuroendocrine neoplasm CD166 clinicopathlogical significance |